Genomics is bringing in a new wave of money from an unlikely group of investors — health systems. More providers are ...

BofA analyst Michael Ryskin lowered the firm’s price target on 10x Genomics (TXG) to $16 from $20 and keeps a Neutral rating on the shares ...

Gene therapy represents a paradigm shift in modern medicine, offering unprecedented opportunities to combat diseases at their ...